[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626096":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":38,"responsibleParty":55,"collaborators":58,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":24,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":24,"enrollmentInfo":73,"targetDuration":24,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":86,"overallStatus":91,"whyStopped":24,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of British Columbia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Early Group - Prescribing portrait audit and feedback","EXPERIMENTAL","The Early Group of clinicians (n=6100) will be mailed the prescribing portrait audit-and-feedback intervention (prescribing portrait, evidence summary, and introduction letter) at the study initiation in February 2026.",[13],"Behavioral: Prescribing portrait audit and feedback",{"label":15,"type":10,"description":16,"interventionNames":17},"Delayed control - Prescribing portrait audit-and-feedback","Delayed control group (n=1526) of clinicians will be mailed the audit-and-feedback intervention (prescribing portrait, evidence summary, and introduction letter) approximately 9 months after Group 1 (Early Group).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BEHAVIORAL","Prescribing portrait audit and feedback","The prescribing portrait audit-and-feedback intervention consists of a confidential, personalized prescribing audit-and-feedback report (Portrait), an evidence-based educational summary (therapeutics letter), and an introduction letter. The prescribing portrait uses linked BC Ministry of Health administrative claims data and presents two key recommendations: (1) reduce the proportion of patient visits resulting in an antibiotic prescription, and (2) avoid routinely prescribing antibiotics for upper respiratory tract infections, acute bronchitis, and acute sinusitis. Each recommendation is accompanied by a bar graph showing the prescriber's 2024 performance compared with the median prescriber in British Columbia and an achievable target. The intervention will be delivered using a secure paper mailing process. During every aspect of production and delivery, prescribing data are confidential and protected.",[15,9],null,[26],{"name":27,"affiliation":5,"role":28},"Colin Dormuth, ScD","PRINCIPAL_INVESTIGATOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"Ellen Reynolds, MPA","CONTACT","1-250-590-5955","ellen.reynolds@ubc.ca",{"name":36,"role":32,"phone":33,"phoneExt":24,"email":37},"Dana Stanley, MET","dana.stanley@ubc.ca",[39],{"facility":40,"status":24,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Therapeutics Initiative - Dept of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia","Vancouver","British Columbia","V6T 1Z3","Canada","CA",{"type":47,"coordinates":48},"Point",[49,50],-123.11934,49.24966,{"lat":50,"lon":49},[53,54],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},{"name":27,"role":28,"phone":24,"phoneExt":24,"email":24},{"type":28,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Colin Dormuth","Associate Professor",[59,62],{"name":60,"class":61},"Ministry of Health, British Columbia","OTHER_GOV",{"name":63,"class":61},"British Columbia Centre for Disease Control","100626096","british-columbia-prescriber-feedback-program---antimicrobial-resistance-100626096",false,"NCT07431190","British Columbia Prescriber Feedback Program - Antimicrobial Resistance","Building a National Framework to Combat Antimicrobial Resistance in Primary Care (CANBuild-AMR): Study Protocol for an Impact Evaluation of the British Columbia Prescriber Feedback Program","Practitioner Inclusion Criteria:\n\nRegistered in 2024 with the BC Medical Services Plan (MSP) with:\n\n* A valid MSP billing number;\n* Status of Salaried, Private Practice, Temporary Licence, or Post Graduate;\n* Prescribed \\>100 dispensed medications in 2024.\n\nExclusion Criteria:\n\n* Previously opted out of the Therapeutics Initiative Portrait program\n\nPatient Exclusion Criteria:\n\n* Age \\\u003C18 years at time of oral antibiotic dispensation;\n* Received PharmaCare benefits through the Palliative Care program at any time during the baseline or study period;\n* Hospitalized within 1 week prior to an antibiotic prescription at any time during the baseline or study period;\n* On chronic suppressive antibiotic therapy (≥90 days' supply of any antibiotic dispensed) during the baseline or study period","ALL","18 Years",{"count":74,"type":75},7626,"ESTIMATED","INTERVENTIONAL",[78],"NA","The goal of this study is to evaluate an educational intervention that aims to reduce the number of unnecessary antibiotics prescribed by family physicians and nurse practitioners in British Columbia, Canada.\n\nThe intervention materials include a confidential personalized prescribing \"portrait\" and an evidence-based educational summary (therapeutics letter), accompanied by an introduction letter.\n\nThe main research questions are:\n\n1. Will the intervention lead to a reduction in the overall number of antibiotics prescriptions started?\n2. Will the intervention lead to a reduction in the proportion of antibiotics prescribed that are likely unnecessary, especially prescriptions for upper respiratory tract infections, acute bronchitis, acute sinusitis?\n\nResearchers will conduct an intervention study with family physicians and nurse practitioners in British Columbia, Canada. Participant clinicians will be randomly assigned to one of two groups. The Early Group will consist of 80% of the participants and will receive the intervention (prescribing portrait, evidence summary, and introduction letter) at the start of the study. The Delayed Group will consist of 20% of participants and will receive the intervention about nine months later. This study design allows most practitioners to receive the intervention early while still allowing time to compare the two groups to assess the impact. To estimate the impact of the intervention, researchers will use administrative health data to compare the prescribing of the Early Group with prescribing of the Delayed Group.",[81,82,83,84,85],"Quality Improvement","Feedback","Prescribing","Antibiotics","Antimicrobial Drug Resistance",[87,88,89,84,90],"Randomized controlled trial","Prescribing feedback","Quality improvement","Antimicrobial resistance","NOT_YET_RECRUITING","2026-02-17",{"date":94,"type":95},"2026-02-24","ACTUAL",{"date":92,"type":75},{"date":98,"type":75},"2028-11-30",{"name":5,"class":6},1]